With the coming threat of Auto tariff, Canada has begone to plan possible retaliation targeting American drug companies. Possibly voiding copyright protection allowing generic reproduction of American drug which will cost these companies billions.
Canadian officials are considering how to take aim at the massive U.S. pharmaceutical industry in the event of a full-blown trade war with the United States, according to an Ottawa-based law professor with knowledge of the situation.
The plan would target valuable U.S. patents, granting Canada’s generic pharmaceutical firms the right to copy, sell and potentially export American drugs.
Amir Attaran, a biomedical scientist and University of Ottawa law professor, said the move would stun Wall Street and the White House, while mobilizing the powerful U.S. pharmaceutical lobby behind Canada’s cause.
“Canadian officials are aware of and studying the proposal in case the United States decides to impose a major retaliation on Canada,” he told Yahoo Canada Finance on Tuesday. “I’m positive it’s being considered.”
Foreign Affairs Minister Chrystia Freeland travelled back to Washington to resume NAFTA negotiations on Wednesday. U.S. officials have demanded a deal by Oct. 1., upping the pressure to resolve long-held sticking points such as the dispute resolution mechanism, cultural protections, and the supply-managed dairy industry.
